BusinessSwitzerlandUK

Hail the antibody, cure with ease

27.03.2012 - The global private equity firm Celtic Therapeutic L.L.L.P. believes in the power of antibody-drug conjugates (ADCs). It is investing $50m in a new Switzerland-based company called ADC Therapeutics Sarl which takes off with ten proprietary ADC oncology programmes in the pipeline.

Among them are ADCs against prostate, lung, renal, breast and blood cancers. Bringing the cytotoxic therapeutics to the desired cancer cells with the help of antibodies has some advantages: ADCs are thought to be target-selective and highly potent. They have fewer side effects and could minimize drug resistance. "We believe that ADCs will represent a significant medical breakthrough in cancer therapy over the coming decade", says Celtic co-founder Stephen Evans-Freke. ADC Therapeutics can rely on the know-how of London's very own Spirogen, an ADC company controlled by Celtic. Spirogen's PBD (proprietary pyrrolobenzodiazepines) 'payload' technology constitutes, if anything, the 'best-in-class' ADC cytotoxic weapon ("warhead"). Scientific wisdom is also provided by British Cancer Research Technology Ltd as a shareholder and US-specialists Samuel Broder and Barrie Ward as non-executive directors. Celtic Therapeutics was founded in 2007 by Evans-Freke and Peter B. Corr, who retired from pharmaceutical giant Pfizer in 2006. Evans-Freke outlines the new company's strategy as follows: "The anticipated investment of up to $50 million into ADC Therapeutics will lead to clinical proof of concept in 2-3 lead oncology programmes. We are committed to fully fund ADC Therapeutics and will raise additional capital if warranted." After having resilient Phase II data promising ADCs could be then contracted to pharma giants.

http://www.european-biotechnology-news.com/news/business/2012-01/hail-the-antibody-cure-with-ease.html

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)23.00 SEK25.00%
  • BAVARIAN NORDIC (D)41.03 EUR20.85%
  • TIGENIX (B)1.02 EUR17.24%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • THROMBOGENICS (B)2.90 EUR-6.15%
  • EVOCUTIS (UK)0.19 GBP-5.00%

TOP

  • KARO BIO (S)38.10 SEK2296.2%
  • TRANSGENE (F)5.08 EUR77.0%
  • BIOTECH PHARMACON (N)12.60 NOK33.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • THROMBOGENICS (B)2.90 EUR-42.5%
  • BIONOR PHARMA (N)1.28 NOK-37.6%

TOP

  • KARO BIO (S)38.10 SEK4546.3%
  • ADOCIA (F)86.70 EUR432.2%
  • VERONA PHARMA (UK)4.92 GBP339.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • BIOTEST (D)19.92 EUR-76.0%
  • NEOVACS (F)0.96 EUR-72.7%

No liability assumed, Date: 30.08.2015